# Semaglutide Improves Hemodynamics in Patients with HFpEF and Obesity Clinical trial shows semaglutide significantly reduces cardiac congestion and improves heart failure markers. - **Source:** [Nature Medicine](https://www.nature.com/nm) - **Published:** 2026-11-08 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/50fc0c5f-1872-4d7b-818b-239ae4c08adc ## Trial Design Overview Researchers conducted a double-blind, placebo-controlled trial involving 81 patients diagnosed with heart failure with preserved ejection fraction and obesity. Participants were randomized to receive either 2.4 mg of semaglutide weekly or a placebo for 52 weeks. The study aimed to evaluate hemodynamic changes through invasive pulmonary artery wedge pressure measurements. ## Primary Outcome Metrics The primary endpoint focused on the change in pulmonary artery wedge pressure during low-intensity exercise. This metric serves as a direct indicator of cardiac congestion in heart failure patients. Researchers also assessed hemodynamic remission, defined as achieving normal pressure levels during both rest and exercise conditions after the one-year treatment period. ## Baseline Patient Characteristics At the start of the study, participants exhibited significant cardiac stress markers. The mean pulmonary artery wedge pressure was measured at 17.5 mmHg during rest and 31.7 mmHg during exercise. These elevated figures established the baseline for evaluating the therapeutic impact of semaglutide compared to the placebo group over 52 weeks. ## Significant Pressure Reductions After 52 weeks, semaglutide treatment led to a mean reduction of 9.8 mmHg in pulmonary artery wedge pressure during exercise. In contrast, the placebo group showed a slight increase of 0.9 mmHg. The estimated difference between the two groups was 10.6 mmHg, demonstrating a statistically significant improvement with a P-value of 0.0001. ## Resting Hemodynamic Improvements Beyond exercise performance, semaglutide also effectively lowered resting pulmonary artery wedge pressures. The study recorded an estimated difference of 7.1 mmHg compared to the placebo group. These findings suggest that the medication provides consistent relief from cardiac filling pressures, potentially alleviating the chronic congestion associated with this specific heart failure phenotype. ## Hemodynamic Remission Rates The trial reported that 53.7% of patients treated with semaglutide achieved hemodynamic remission, compared to only 7.4% in the placebo arm. This represents an odds ratio of 14.1, highlighting the substantial clinical benefit of the intervention. Remission was defined by maintaining normal pressure thresholds during both rest and exercise at 52 weeks. ## Mechanism of Action While the exact mechanisms remain under investigation, the results indicate that semaglutide reduces left heart filling pressures. This effect is observed both at rest and during physical exertion. The study provides critical data on how GLP-1 receptor agonists influence cardiac function in patients struggling with both obesity and preserved ejection fraction heart failure. ## Study Funding Sources This research was supported by the Congressionally Directed Medical Research Programs under award number W81XWH2210245. Additionally, the National Heart, Lung, and Blood Institute provided support through multiple grants, including R01 HL128526 and U01 HL160226. Novo Nordisk supplied the semaglutide and matching placebo used throughout the duration of this clinical trial. ## Data Sharing Policy Individual participant data will be made available at the discretion of the corresponding author upon request. Access requires the execution of a data use agreement and a 30-day review period. The decision process evaluates whether the proposed use is scientifically coherent and if the data can be shared with acceptably low privacy risks. ## Clinical Implications The findings suggest that semaglutide is a potent therapeutic option for managing obesity-related heart failure. By significantly lowering cardiac filling pressures, the drug addresses a core pathophysiological target in this patient population. These results support the growing body of evidence regarding the cardiovascular benefits of incretin-based therapies in complex metabolic and heart conditions. ## Future Research Directions Future studies should continue to explore the long-term impact of weight-dependent and weight-independent drivers of therapeutic benefit. Researchers are currently investigating how these hemodynamic improvements translate into long-term mortality and morbidity outcomes. Continued analysis of the CAMEO-SEMA trial and similar studies will further clarify the role of semaglutide in clinical cardiology practice. ## Sources covering this story - https://www.nature.com/articles/s41591-026-04762-3 — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._